Improving data sharing to increase the efficiency of antibiotic R&D

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Nature Reviews Drug Discovery 20, 1-2 (2021)

doi: https://doi.org/10.1038/d41573-020-00185-y


  1. 1.

    Erwin, A. L. Antibacterial drug discovery targeting the lipopolysaccharide biosynthetic enzyme. Cold Spring Harb. Perspect. Med. https://doi.org/10.1101/cshperspect.a025304 (2016)

  2. 2.

    Kalinin, D. V. & Holl, R. LpxC inhibitors: a patent review (2010-2016). Expert Opin. Ther. Pat. 27, 1227–1250 (2017).

    PubMed  Article  Google Scholar 

  3. 3.

    Butler, M. S. & Paterson, D. L. Antibiotics in the clinical pipeline in October 2019. J. Antibiot. 73, 329–364 (2020).

    PubMed  Article  Google Scholar 

  4. 4.

    Cohen, F. et al. Optimization of LpxC inhibitors for antibacterial activity and cardiovascular safety. ChemMedChem 14, 1–14 (2019).

    PubMed  Article  Google Scholar 

  5. 5.

    Krause, K. M. et al. Potent LpxC inhibitors with in vitro activity against multidrug-resistant pseudomonas aeruginosa. Antimicrob. Agents Chemother. 63, e00977-19 (2019)

    PubMed  Article  Google Scholar 

Download references

Competing Interests

Z.Z. is a co-founder, shareholder and the CEO of Forge Therapeutics. Forge Therapeutics currently receives funding support from CARB-X. K.O. is the PI for grants for CARB-X from the Biomedical Advanced Research & Development Authority (Cooperative Agreement No. 6 IDSEP160030), the Wellcome Trust, the UK Department of Health & Social Care (GAMRIF), the German Federal Ministry of Education & Research (BMBF) and the Bill & Melinda Gates Foundation. The views expressed herein are personal, and are not necessarily the views of CARB-X or any CARB-X funder. The other authors declare no competing interests.

Nature Briefing

An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday.

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing